Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive
23 April 2014
(101.95 Kb 29 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 April 2014